Osimertinib-induced cardiopulmonary toxicity: a network toxicology, molecular docking, and molecular dynamics simulation study

Lung cancer remains one of the most formidable challenges in modern medicine, particularly a type known as non-small cell lung cancer. For patients whose tumors carry a specific genetic mutation, doctors often turn to a powerful class of drugs called tyrosine kinase inhibitors. These medications act like precision-guided tools, designed to shut down the faulty signals that tell cancer cells to grow and divide. One such drug, osimertinib, has become a standard treatment because it is highly effective at targeting resistant forms of the disease. However, the body is a complex system where a change in one area can ripple through others. While these drugs fight cancer, they can sometimes cause unintended harm to healthy organs, specifically the heart and the lungs. This dual threat creates a difficult situation for patients and doctors: the very medicine that saves a life can also damage the organs essential for living. Understanding exactly how a single drug can injure two different organs at the same time is a puzzle that has long needed solving.

A team of researchers set out to map the invisible pathways through which osimertinib causes this simultaneous damage. Instead of testing the drug on patients or animals first, they built a detailed digital model of the biological interactions. They began by gathering a massive list of genes known to be involved in heart problems and lung diseases, then cross-referenced this with a list of proteins that osimertinib is known to interact with. This process narrowed thousands of possibilities down to a small group of shared targets. The researchers found that the drug likely affects a specific set of seven key proteins that act as master switches for gene activity. These proteins do not just sit idle; they work together to regulate how genetic instructions are read and executed within cells. The study suggests that osimertinib disrupts the delicate balance between these switches, throwing the cellular machinery of both the heart and lungs into disarray.

To verify these findings, the scientists used computer simulations to watch how the drug molecule physically attaches to these target proteins. They found that osimertinib binds tightly to all seven of the identified proteins, much like a key fitting into a lock. The binding was so strong that the researchers focused their attention on two specific proteins, HDAC1 and CREBBP, to see what happened over time. Using advanced molecular dynamics simulations, they watched the drug and the protein interact for a simulated period equivalent to 100 nanoseconds. The results showed that the drug did not just bump into the protein and fall away; it settled into a stable position, forming strong connections that held it in place. The energy required to pull the drug away was significant, indicating a very firm grip. This stable attachment suggests that the drug is likely to stay bound long enough to interfere with the protein's normal job.

The core of the discovery lies in what these proteins actually do. The study points to a system of epigenetic regulation, which can be thought of as the volume control for genes. Some of the proteins identified, such as CREBBP and EP300, act to turn genes on by adding chemical tags that make the DNA more accessible. Others, like HDAC1 and HDAC2, act to turn genes off by removing those tags. Under normal conditions, these opposing forces work in harmony to keep the cell functioning correctly. The researchers propose that osimertinib disrupts this balance. By binding to these proteins, the drug may prevent them from doing their jobs properly, leading to a chaotic mix of genes being turned on or off when they should not be. This disruption appears to affect the heart and lungs because these organs rely heavily on this precise genetic tuning to maintain their structure and function.

The analysis also revealed that these seven target proteins are connected to broader biological pathways known to be involved in cancer and inflammation. For instance, the study highlighted a pathway involving microRNAs, which are small molecules that help regulate gene expression, and a major signaling route known as the PI3K-Akt pathway. These connections suggest that the drug's toxicity is not a random event but a result of a specific, multi-target interference with the cell's internal communication network. The researchers identified that the drug interacts with proteins like TP53, which helps protect cells from damage, and ESR1, which is involved in hormone signaling. When these systems are disturbed simultaneously, the result is a cascade of effects that manifests as heart failure or lung inflammation.

It is important to note that these findings come from computer models and simulations, not from direct observation in living patients. The researchers used powerful software to predict how the drug behaves, and while the results are consistent and stable within the simulation, they represent a theoretical framework rather than a confirmed clinical fact. The study does not claim to have proven that this is exactly how the toxicity happens in every patient, but rather that this is a highly plausible mechanism based on the physical and chemical properties of the drug and its targets. The authors emphasize that their work provides a roadmap for future experiments, suggesting that scientists should now look for these specific interactions in biological samples to confirm the theory.

Ultimately, this research offers a new way of thinking about drug side effects. Instead of viewing the heart and lung damage as separate, unrelated problems, the study suggests they are two symptoms of the same underlying cause: a disruption of the epigenetic balance that controls how cells function. By identifying the specific proteins involved, the study gives doctors and scientists a clearer picture of what to watch for and potentially how to intervene. If future research confirms that osimertinib binds to these proteins in the human body, it may open the door to developing strategies that protect the heart and lungs while still allowing the drug to fight the cancer. For now, the work stands as a detailed map of a complex biological landscape, showing how a single molecule can ripple through the body's most vital systems.